Details

Autor(en) / Beteiligte

• van Doremalen, Neeltje
• Lambe, Teresa
• Spencer, Alexandra
• Belij-Rammerstorfer, Sandra
• Purushotham, Jyothi N
• Port, Julia R
• Avanzato, Victoria A
• Bushmaker, Trenton
• Flaxman, Amy
• Ulaszewska, Marta
• Feldmann, Friederike
• Allen, Elizabeth R
• Sharpe, Hannah
• Schulz, Jonathan
• Holbrook, Myndi
• Okumura, Atsushi
• Meade-White, Kimberly
• Pérez-Pérez, Lizzette
• Edwards, Nick J
• Wright, Daniel
• Bissett, Cameron
• Gilbride, Ciaran
• Williamson, Brandi N
• Rosenke, Rebecca
• Long, Dan
• Ishwarbhai, Alka
• Kailath, Reshma
• Rose, Louisa
• Morris, Susan
• Powers, Claire
• Lovaglio, Jamie
• Hanley, Patrick W
• Scott, Dana
• Saturday, Greg
• de Wit, Emmie
• Gilbert, Sarah C
• Munster, Vincent J

Titel

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Ist Teil von

• Nature (London), 2020-10, Vol.586 (7830), p.578-582

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and is responsible for the coronavirus disease 2019 (COVID-19) pandemic . Vaccines are an essential countermeasure and are urgently needed to control the pandemic . Here we show that the adenovirus-vector-based vaccine ChAdOx1 nCoV-19, which encodes the spike protein of SARS-CoV-2, is immunogenic in mice and elicites a robust humoral and cell-mediated response. This response was predominantly mediated by type-1 T helper cells, as demonstrated by the profiling of the IgG subclass and the expression of cytokines. Vaccination with ChAdOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cellular immune response of type-1 and type-2 T helper cells in rhesus macaques. We observed a significantly reduced viral load in the bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques that were challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated SARS-CoV-2-infected animals. However, there was no difference in nasal shedding between vaccinated and control SARS-CoV-2-infected macaques. Notably, we found no evidence of immune-enhanced disease after viral challenge in vaccinated SARS-CoV-2-infected animals. The safety, immunogenicity and efficacy profiles of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomized controlled clinical trials in humans.